Foghorn Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Stock-Based Compensation Growth & History (FHTX)
Foghorn Therapeutics's stock-based compensation was $10.4M for fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.4M | −$1.5M | −12.56% |
| 2024 | 2024-12-31 | $11.9M | −$4.3M | −26.52% |
| 2023 | 2023-12-31 | $16.2M | $1.9M | +12.90% |
| 2022 | 2022-12-31 | $14.3M | $6.0M | +70.99% |
| 2021 | 2021-12-31 | $8.4M | $5.4M | +183.15% |
| 2020 | 2020-12-31 | $3.0M | $1.3M | +74.79% |
| 2019 | 2019-12-31 | $1.7M | — | — |
Foghorn Therapeutics quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | −$183,000 | −6.70% |
| Q1 2026 | 2026-03-31 | $2.4M | −$309,000 | −11.48% |
| Q4 2025 | 2025-12-31 | $2.2M | −$242,000 | −9.75% |
| Q3 2025 | 2025-09-30 | $2.7M | −$285,000 | −9.44% |
| Q2 2025 | 2025-06-30 | $2.7M | −$435,000 | −13.73% |
| Q1 2025 | 2025-03-31 | $2.7M | −$532,000 | −16.50% |
| Q4 2024 | 2024-12-31 | $2.5M | −$567,000 | −18.59% |
| Q3 2024 | 2024-09-30 | $3.0M | −$1.1M | −26.28% |
| Q2 2024 | 2024-06-30 | $3.2M | −$1.3M | −29.13% |
| Q1 2024 | 2024-03-31 | $3.2M | −$1.3M | −29.48% |
| Q4 2023 | 2023-12-31 | $3.0M | −$731,000 | −19.33% |
| Q3 2023 | 2023-09-30 | $4.1M | $292,000 | +7.68% |
| Q2 2023 | 2023-06-30 | $4.5M | $961,000 | +27.39% |
| Q1 2023 | 2023-03-31 | $4.6M | $1.3M | +40.94% |
| Q4 2022 | 2022-12-31 | $3.8M | $1.7M | +81.43% |
| Q3 2022 | 2022-09-30 | $3.8M | $1.4M | +60.42% |
| Q2 2022 | 2022-06-30 | $3.5M | $1.5M | +71.84% |
| Q1 2022 | 2022-03-31 | $3.2M | $1.4M | +71.82% |
| Q4 2021 | 2021-12-31 | $2.1M | $1.0M | +93.32% |
| Q3 2021 | 2021-09-30 | $2.4M | $1.5M | +170.24% |
| Q2 2021 | 2021-06-30 | $2.0M | $1.6M | +317.59% |
| Q1 2021 | 2021-03-31 | $1.9M | $1.4M | +265.18% |
| Q4 2020 | 2020-12-31 | $1.1M | — | — |
| Q3 2020 | 2020-09-30 | $877,000 | $434,000 | +97.97% |
| Q2 2020 | 2020-06-30 | $489,000 | — | — |
| Q1 2020 | 2020-03-31 | $517,000 | — | — |
| Q3 2019 | 2019-09-30 | $443,000 | — | — |
Foghorn Therapeutics stock-based compensation trends
Over the last five fiscal years, Foghorn Therapeutics's stock-based compensation increased from $3.0M to $10.4M, a change of $7.4M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗